« Return to News | Technology Solutions

CoreRx launches FLEXITAB

Monday, November 7, 2011 12:27 PM

CoreRx has further enhanced its offering by adding the Bosch Manesty FLEXITAB, a fully automated, single station tablet press with a multi-layer tablet function, giving it the unique capacity to produce multi-layer (up to three-layer) tablets using a minimal amount of material. Its variable punch displacement and dwell time can be set to simulate compression on any rotary press using compression forces up to100kN.

“CoreRx is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times,” said Mark Licarde, CoreRx’s VP of manufacturing. Licarde added, “We will continue to add to capabilities in response to client requirements for preclinical and early phase combination product clinical GMP supply. The FLEXITAB decreases setup time and API use – generating significant cost savings to our clients.”

Able to produce 3-layer tablets, the Bosch Manesty FLEXITAB fully automated, single-station tablet press supports production of small batches. All parameters are adjustable, which allows for simulation of any rotary tablet press at any given speed. Hydraulic and pneumatic cylinders enable compression forces of 100 kN and rapid punch displacement. In addition, press includes TFT touch screen panel PC, PLC-based control system, and FLEXITAB software.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.